Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Labeling Standards Top Kennedy’s Agenda For Commissioner Nominee

Executive Summary

FDA will base its regulation of product labeling "on the science about how the public understands and interprets information on labels," Commissioner-nominee Mark McClellan told the Senate Health Committee Oct. 7

You may also be interested in...



FDA Readies Report On DTC, Says Physician Survey Supports Current Policy

FDA expects to publish a report on its 1997 direct-to-consumer broadcast advertising policy this spring

FDA Readies Report On DTC, Says Physician Survey Supports Current Policy

FDA expects to publish a report on its 1997 direct-to-consumer broadcast advertising policy this spring

First Amendment Case Law Allows FDA To Dictate Warnings – AARP

First Amendment case law leaves FDA with ample authority to require specific warnings in product promotions, AARP maintains

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel